약물과용두통: 진단기준, 역학, 치료

키워드

참고문헌 (66)

1. Headache Classification Committee of the International Headache Society(IHS), "The International Classification of Headache Disorders, 3rd edition", Cephalalgia, 38, pp.1~211 (2018)
2. Straube A, "Prevalence of chronic migraine and medication overuse headache in Germany--the German DMKG headache study", Cephalalgia, 30, pp.207~213 (2010)
3. Jonsson P, "Epidemiology of medication overuse headache in the general Swedish population", Cephalalgia, 31, pp.1015~1022 (2011)
4. Jellestad PL, "Economic benefits of treating medication-overuse headache-results from the multicenter COMOESTAS project", Cephalalgia, 39, pp.274~285 (2019)
5. Zwart JA, "Depression and anxiety disorders associated with headache frequency. The Nord-Trøndelag Health Study", Eur J Neurol, 10, pp.147~152 (2003)
6. GBD 2015 Disease and Injury incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015", Lancet, 388, pp.1545~1602 (2016)
7. Steiner TJ, "Headache disorders are third cause of disability worldwide", J Headache Pain, 16, pp.58~ (2015)
8. GBD 2015 Neurological Disorders Collaborator Group, "Global, regional, and national burden of neurological disorders during 1990-2015 : a systematic analysis for the Global Burden of Disease Study 2015", Lancet Neurol, 16, pp.877~897 (2017)
9. Ashina M, "Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study(PROMISE-1)", Cephalalgia, 40, pp.241~254 (2020)
10. Dodick DW, "Eptinezumab for prevention of chronic migraine : a randomized phase 2b clinical trial", Cephalalgia, 39, pp.1075~1085 (2019)
11. Tepper S, "Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2 trial", Lancet Neurol, 16, pp.425~434 (2017)
12. Goadsby PJ, "A controlled trial of erenumab for episodic migraine", N Engl J Med, 377, pp.2123~2132 (2017)
13. Silberstein SD, "Fremanezumab for the preventive treatment of chronic migraine", N Engl J Med, 377, pp.2113~2122 (2017)
14. Dodick DW, "Effect of fremanezumab compared with placebo for prevention of episodic migraine : a randomized clinical trial", JAMA, 319, pp.1999~2008 (2018)
15. Detke HC, "Galcanezumab in chronic migraine : the randomized, double-blind, placebo-controlled REGAIN study", Neurology, 91, pp.e2211~e2221 (2018)
16. Skljarevski V, "Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 Phase 3 randomized controlled clinical trial", Cephalalgia, 38, pp.1442~1454 (2018)
17. Stauffer VL, "Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial", JAMA Neurol, 75, pp.1080~1088 (2018)
18. Dodick DW, "Medication overuse in a subgroup analysis of phase 3 placebocontrolled studies of galcanezumab in the prevention of episodic and chronic migraine", Cephalalgia, 41, pp.340~352 (2021)
19. Diener HC, "Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medicationoveruse headache : subgroup analysis of PROMISE-2", Headache, 61, pp.125~136 (2021)
20. Silberstein SD, "The impact of fremanezumab on medication overuse in patients with chronic migraine : subgroup analysis of the HALO CM study", J Headache Pain, 21, pp.114~ (2020)
21. Tepper SJ, "Erenumab in chronic migraine with medication overuse : subgroup analysis of a randomized trial", Neurology, 92, pp.e2309~e2320 (2019)
22. Diener HC, "European Academy of Neurology guideline on the management of medication-overuse headache", Eur J Neurol, 27, pp.1102~1116 (2020)
23. Bendtsen L, "Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd edition, 2012", J Headache Pain, 13(Suppl 1), pp.S1~S29 (2012)
24. "Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society", Cephalalgia, 8(Suppl 7), pp.1~96 (1988)
25. Headache Classification Subcommittee of the International Headache Society, "The International Classification of Headache Disorders : 2nd edition", Cephalalgia, 24(Suppl 1), pp.9~160 (2004)
26. Silberstein SD, "The International Classification of Headache Disorders, 2nd edition (ICHD-II)--revision of criteria for 8.2 medication-overuse headache", Cephalalgia, 25, pp.460~465 (2005)
27. Headache Classification Committee of the International Headache Society, "The International Classification of Headache Disorders, 3rd edition(beta version)", Cephalalgia, 33, pp.629~808 (2013)
28. Westergaard ML, "Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates : a systematic review", Cephalalgia, 34, pp.409~425 (2014)
29. Wang SJ, "Chronic daily headache in Chinese elderly : prevalence, risk factors, and biannual follow-up", Neurology, 54, pp.314~319 (2000)
30. Prencipe M, "Prevalence of headache in an elderly population : attack frequency, disability, and use of medication", J Neurol Neurosurg Psychiatry, 70, pp.377~381 (2001)
31. Westergaard ML, "Prevalence of chronic headache with and without medication overuse : associations with socioeconomic position and physical and mental health status", Pain, 155, pp.2005~2013 (2014)
32. Shand B, "Clinical and demographical characteristics of patients with medication overuse headache in argentina and Chile : analysis of the Latin American section of COMOESTAS project", J Headache Pain, 16, pp.83~ (2015)
33. Park HK, "Interim analysis of the Registry for Load and Management of Medication Overuse Headache(RELEASE) : a multicenter, comprehensive medication overuse headache registry", Cephalalgia, 42, pp.455~465 (2022)
34. Schwedt TJ, "Headache characteristics and burden from chronic migraine with medication overuse headache : crosssectional observations from the medication overuse treatment strategy trial", Headache, 61, pp.351~362 (2021)
35. Carlsen LN, "Comparison of 3 treatment strategies for medication overuse headache : a randomized clinical trial", JAMA Neurol, 77, pp.1069~1078 (2020)
36. Viana M, "Clinical subtypes of medication overuse headache-findings from a large cohort", Headache, 59, pp.1481~1491 (2019)
37. Diener HC, "Medication-overuse headache : risk factors, pathophysiology and management", Nat Rev Neurol, 12, pp.575~583 (2016)
38. Bendtsen L, "Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project)", Cephalalgia, 34, pp.426~433 (2014)
39. Rossi P, "Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs", Cephalalgia, 26, pp.1097~1105 (2006)
40. Kristoffersen ES, "Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial", J Neurol Neurosurg Psychiatry, 86, pp.505~512 (2015)
41. Kristoffersen ES, "Lasting improvement of medication-overuse headache after brief intervention-a long-term follow-up in primary care", Eur J Neurol, 24, pp.883~891 (2017)
42. Zeeberg P, "Discontinuation of medication overuse in headache patients : recovery of therapeutic responsiveness", Cephalalgia, 26, pp.1192~1198 (2006)
43. Carlsen LN, "Complete detoxification is the most effective treatment of medicationoveruse headache : a randomized controlled open-label trial", Cephalalgia, 38, pp.225~236 (2018)
44. Rossi P, "A narrative review on the management of medication overuse headache : the steep road from experience to evidence", J Headache Pain, 10, pp.407~417 (2009)
45. Katsarava Z, "Medication-overuse headache", Curr Opin Neurol, 26, pp.276~281 (2013)
46. Katsarava Z, "Clinical features of withdrawal headache following overuse of triptans and other headache drugs", Neurology, 57, pp.1694~1698 (2001)
47. Relja G, "Outcome of medication overuse headache after abrupt in-patient withdrawal", Cephalalgia, 26, pp.589~595 (2006)
48. Krymchantowski AV, "Prednisone as initial treatment of analgesic-induced daily headache", Cephalalgia, 20, pp.107~113 (2000)
49. Paolucci M, "Methylprednisolone plus diazepam i.v. as bridge therapy for medication overuse headache", Neurol Sci, 38, pp.2025~2029 (2017)
50. Bøe MG, "Prednisolone does not reduce withdrawal headache : a randomized, double-blind study", Neurology, 69, pp.26~31 (2007)
51. Pageler L, "Prednisone vs. placebo in withdrawal therapy following medication overuse headache", Cephalalgia, 28, pp.152~156 (2008)
52. Rabe K, "Prednisone for the treatment of withdrawal headache in patients with medication overuse headache : a randomized, double-blind, placebo-controlled study", Cephalalgia, 33, pp.202~207 (2013)
53. Cevoli S, "Treatment of withdrawal headache in patients with medication overuse headache : a pilot study", J Headache Pain, 18, pp.56~ (2017)
54. Vandenbussche N, "Medication-overuse headache : a widely recognized entity amidst ongoing debate", J Headache Pain, 19, pp.50~ (2018)
55. Pensato U, "Detoxification vs non-detoxification before starting an antiCGRP monoclonal antibody in medication overuse headache", Cephalalgia, 42, pp.645~653 (2022)
56. Diener HC, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial", Cephalalgia, 30, pp.804~814 (2010)
57. Aurora SK, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial", Cephalalgia, 30, pp.793~803 (2010)
58. Dodick DW, "OnabotulinumtoxinA for treatment of chronic migraine : pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program", Headache, 50, pp.921~936 (2010)
59. Silberstein SD, "OnabotulinumtoxinA for treatment of chronic migraine : PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline", J Neurol Sci, 331, pp.48~56 (2013)
60. Sandrini G, "Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache : a multicenter, double-blind, randomized, placebo-controlled, parallel group study", J Headache Pain, 12, pp.427~433 (2011)
61. Pijpers JA, "Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse : a double-blind randomized controlled trial", Brain, 142, pp.1203~1214 (2019)
62. Diener HC, "Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse", Cephalalgia, 29, pp.1021~1027 (2009)
63. Sarchielli P, "Sodium valproate in migraine without aura and medication overuse headache : a randomized controlled trial", Eur Neuropsychopharmacol, 24, pp.1289~1297 (2014)
64. Chiang CC, "Treatment of medication-overuse headache : a systematic review", Cephalalgia, 36, pp.371~386 (2016)
65. Raggi A, "Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse : a longitudinal observational study", Headache, 57, pp.60~70 (2017)
66. Tassorelli C, "The added value of an electronic monitoring and alerting system in the management of medication-overuse headache : a controlled multicentre study", Cephalalgia, 37, pp.1115~1125 (2017)

관련 논문AI추천